{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-094109","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.112858+00:00","generated_at":"2026-05-17T05:25:59.863086+00:00","sec_items":["1.01","5.03","3.02","3.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b","bullets":["Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).","Consideration: 382,034 common shares + 179.1878 Series A-2 Preferred shares (convert 1:10,000), representing 7.31% fully diluted.","Phase 1b CIPN study fully funded by NCI; patient enrollment projected first half 2026.","Halneuron Phase 2b ongoing (80 patients randomized); interim data from 90-100 patients expected December 2025.","Support agreements with Serpin, Tungsten, and Sealbond to vote for stockholder approval of preferred stock conversions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-094109","json":"https://secwatch.observer/filing/0001104659-25-094109.json","markdown":"https://secwatch.observer/filing/0001104659-25-094109.md","text":"https://secwatch.observer/filing/0001104659-25-094109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925094109/0001104659-25-094109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925094109/dwtx-20250929x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:25:59.863086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ed386d5c0eeb6f186a4380792df5dbbdfa0f5d6","claim":"Dogwood Therapeutics, Inc.: Company filed a Certificate of Designation for Series A-2 Non-Voting Convertible Preferred Stock, establishing preferences, rights, and limitations including voting restrictions, dividend prohibition, conversion rights, and protective provisions (effective 2025-09-29).","evidence_excerpt":"On September 29, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A-2 Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Serpin Registration Rights Agreement referenced in Item 1.01 above.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925094109/0001104659-25-094109-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-09-29"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}